Novo Nordisk has announced plans to present 11 scientific abstracts at the upcoming 76th Annual American Association for the Study of Liver Diseases (AASLD) congress, The Liver Meeting® 2025, scheduled from 7 to 11 November in Washington, D.C., U.S. The presentations will feature both clinical trial findings and real-world evidence exploring the role of Wegovy® (semaglutide 2.4 mg) in metabolic dysfunction-associated steatohepatitis (MASH), with a particular focus on its relationship to weight loss and efficacy across diverse patient populations.
In addition to semaglutide data, Novo Nordisk will also present real-world analyses examining the utility of non-invasive tests (NITs) in improving the evaluation and management of MASH, an increasingly prevalent liver condition linked to metabolic dysfunction and obesity.
“The breadth and depth of our clinical trial program illustrates our abiding commitment to improve health outcomes for patients with serious chronic diseases, including MASH,” said Martin Holst Lange, Chief Scientific Officer and Executive Vice President, Research & Development at Novo Nordisk. “These post-hoc analyses of the ESSENCE trial help to provide insight into clinical effects of semaglutide 2.4 mg across different stages of MASH disease progression, as well as within diverse population subgroups.”
The upcoming presentations underscore Novo Nordisk’s leadership in advancing research on optimal screening, diagnosis, and management of MASH and related chronic metabolic diseases. By integrating insights from both clinical trials and real-world data, the company continues to expand scientific understanding of semaglutide’s potential therapeutic role beyond diabetes and obesity management.
The accepted poster and oral presentations at The Liver Meeting® 2025 include preliminary data, which may be subject to updates in the final published manuscripts. Detailed session dates and presentation times are available on the AASLD official website.
Also Read